Nemocnica S Poliklinikou Myjava So Sidlom V Myjave
- Address
- Staromyjavska 712/59, 907 01 Myjava, Slovakia
Nemocnica S Poliklinikou Myjava - Cardiorenal Research Center
Nemocnica S Poliklinikou Myjava is a specialized medical research facility focusing on advancing treatment strategies for complex cardiorenal conditions. The center demonstrates particular expertise in investigating novel therapeutic combinations for patients with chronic kidney disease (CKD) and associated cardiovascular complications, including hypertension and heart failure.
- Chronic kidney disease progression and hypertension management with combination therapies
- Heart failure with impaired kidney function and cardiovascular mortality prevention
- Clinical outcomes research using eGFR monitoring and composite cardiovascular endpoints
The research center is actively involved in Phase III clinical trials evaluating innovative pharmacological interventions, particularly investigating the efficacy of baxdrostat and balcinrenone in combination with dapagliflozin. Their research portfolio emphasizes protecting kidney function through sustained eGFR improvement, reducing cardiovascular death risk, and preventing heart failure events in patients with complex cardiorenal syndrome.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1AstraZeneca AB2active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB3trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 353 other sites in Slovakia
Therapeutic Area Benchmark — Slovakia
Select a therapeutic area to compare against other sites in Slovakia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Slovakia
Market Share
Country: Slovakia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Nemocnica S Poliklinikou Myjava So Sidlom V Myjave
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Baxdrostat and Dapagliflozin on Renal and Cardiovascular Outcomes in Chronic Kidney Disease with Hypertension | AstraZeneca AB | Phase III | Recruiting | May 2025 | — |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dapagliflozin | 3 | Unknown | 2024-06-05 | 2025-05-07 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.